{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:55:38Z","timestamp":1772160938817,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Israel Institute for Biological Research","award":["SB-5118-274"],"award-info":[{"award-number":["SB-5118-274"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The global increase in multidrug-resistant (MDR) pathogenic bacteria has led to growing interest in bacteriophage (\u201cphage\u201d) therapy. Therapeutic phages are usually selected based on their ability to infect and lyse target bacteria, using in vitro assays. In these assays, phage infection is determined using target bacteria grown in standard commercial rich media, while evaluation of the actual therapeutic activity requires the presence of human blood. In the present work, we characterized the ability of two different Yersinia pestis lytic phages (\u03d5A1122 and PST) to infect and kill a luminescent Y. pestis EV76 strain suspended in Brain Heart Infusion (BHI)-rich medium or in human whole blood, simulating the host environment. We found that the ability of the phages to infect and lyse blood-suspended Y. pestis was not correlated with their ability to infect and lyse BHI-suspended bacteria. While the two different phages exhibited efficient infective capacity in a BHI-suspended culture, only the PST phage showed efficient lysis ability against blood-suspended bacteria. Therefore, we recommend that for personalized phage therapy, selection of phage(s) for efficient treatment of patients suffering from MDR bacterial infections should include prior testing of the candidate phage(s) for their lysis ability in the presence of human blood.<\/jats:p>","DOI":"10.3390\/v13010089","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T20:32:47Z","timestamp":1610397167000},"page":"89","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Characterization of Yersinia pestis Phage Lytic Activity in Human Whole Blood for the Selection of Efficient Therapeutic Phages"],"prefix":"10.3390","volume":"13","author":[{"given":"Sarit","family":"Moses","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaron","family":"Vagima","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avital","family":"Tidhar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Aftalion","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-293X","authenticated-orcid":false,"given":"Emanuelle","family":"Mamroud","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahar","family":"Rotem","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-8477","authenticated-orcid":false,"given":"Ida","family":"Steinberger-Levy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fmicb.2010.00134","article-title":"A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future","volume":"1","author":"Aminov","year":"2010","journal-title":"Front. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/MMBR.00016-10","article-title":"Origins and Evolution of Antibiotic Resistance","volume":"74","author":"Davies","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","unstructured":"World Health Organization (2019). Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, World Health Organization."},{"key":"ref_5","unstructured":"World Health Organization (2019). Antibacterial Agents in Preclinical Development: An Open Access Database, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bies.201400152","article-title":"A century of phage research: Bacteriophages and the shaping of modern biology","volume":"37","author":"Keen","year":"2015","journal-title":"BioEssays"},{"key":"ref_7","first-page":"329","article-title":"Bacteriophage as a Treatment in Acute Medical and Surgical Infections","volume":"7","year":"1931","journal-title":"Bull. N. Y. Acad. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","article-title":"Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model","volume":"21","author":"Anand","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1128\/AAC.01513-06","article-title":"Experimental Phage Therapy against Staphylococcus aureus in Mice","volume":"51","author":"Capparelli","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chhibber, S., Kaur, T., and Kaur, S. (2013). Co-Therapy Using Lytic Bacteriophage and Linezolid: Effective Treatment in Eliminating Methicillin Resistant Staphylococcus aureus (MRSA) from Diabetic Foot Infections. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056022"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.resmic.2018.04.008","article-title":"Combined bacteriophages and antibiotics as an efficient therapy against VRE Enterococcus faecalis in a mouse model","volume":"169","author":"Gelman","year":"2018","journal-title":"Res. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcimb.2019.00022","article-title":"Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy","volume":"9","author":"Tagliaferri","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Abdelkader, K., Gerstmans, H., Saafan, A., Dishisha, T., and Briers, Y. (2019). The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole. Viruses, 11.","DOI":"10.3390\/v11020096"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41587-019-0133-z","article-title":"Phage therapy\u2019s latest makeover","volume":"37","author":"Schmidt","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1709-y","article-title":"Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury\u2014A case report","volume":"21","author":"Jennes","year":"2017","journal-title":"Crit. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","article-title":"Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection","volume":"5","author":"Lavergne","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/cid\/ciz222","article-title":"Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection with Bacteriophages and Antibiotics Combination","volume":"69","author":"Gelman","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Schooley, R.T., Biswas, B., Gill, J.J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J.J., Reed, S.L., Rohwer, F., and Benler, S. (2017). Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails to Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00954-17"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a Biological Weapon","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tim.2015.11.008","article-title":"Pneumonic Plague: The Darker Side of Yersinia pestis","volume":"24","author":"Pechous","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1099\/jmm.0.000915","article-title":"The rise of pneumonic plague in Madagascar: Current plague outbreak breaks usual seasonal mould","volume":"68","author":"Rabaan","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/08998280.2005.11928049","article-title":"Plague: From Natural Disease to Bioterrorism","volume":"Volume 18","author":"Riedel","year":"2005","journal-title":"Baylor University Medical Center Proceedings"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yang, R. (2017). Plague: Recognition, Treatment, and Prevention. J. Clin. Microbiol., 56.","DOI":"10.1128\/JCM.01519-17"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijantimicag.2017.09.015","article-title":"Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat","volume":"51","author":"Cabanel","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.00306-06","article-title":"Resistance of Yersinia pestis to Antimicrobial Agents","volume":"50","author":"Galimand","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Welch, T.J., Fricke, W.F., McDermott, P.F., White, D.G., Rosso, M.-L., Rasko, D.A., Mammel, M.K., Eppinger, M., Rosovitz, M., and Wagner, D. (2007). Multiple Antimicrobial Resistance in Plague: An Emerging Public Health Risk. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000309"},{"key":"ref_29","first-page":"13815","article-title":"Propagation of S. aureus Phage K in Presence of Human Blood","volume":"18","author":"Frati","year":"2019","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"ref_30","first-page":"1","article-title":"Metals Enhance the Killing of Bacteria by Bacteriophage in Human Blood","volume":"8","author":"Ma","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fmicb.2018.00741","article-title":"Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model","volume":"9","author":"Gur","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_32","first-page":"763","article-title":"A Rapid Molecular Test for Determining Yersinia pestis Susceptibility to Ciprofloxacin by the Quantification of Differentially Expressed Marker Genes","volume":"7","author":"Shifman","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yang, R., and Anisimov, A. (2016). Bacteriophages of Yersinia pestis. Yersinia Pestis: Retrospective and Perspective, Springer.","DOI":"10.1007\/978-94-024-0890-4"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1128\/JB.00339-11","article-title":"Identification of the Lipopolysaccharide Core of Yersinia pestis and Yersinia pseudotuberculosis as the Receptor for Bacteriophage A1122","volume":"193","author":"Kiljunen","year":"2011","journal-title":"J. Bacteriol."},{"key":"ref_35","unstructured":"Elizabeth Kutter, A.S. (2005). Working with Bacteriophages: Common Techniques and Methodological Approaches, CRC Press. [1st ed.]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5694\/mja2.50355","article-title":"Phage therapy for severe bacterial infections: A narrative review","volume":"212","author":"Fabijan","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4161\/bact.21440","article-title":"Development of a high throughput assay for indirectly measuring phage growth using the OmniLogTMsystem","volume":"2","author":"Henry","year":"2012","journal-title":"Bacteriophage"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1128\/JCM.01533-09","article-title":"Diagnostic Bioluminescent Phage for Detection of Yersinia pestis","volume":"47","author":"Schofield","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1128\/JB.185.17.5248-5262.2003","article-title":"The Genome Sequence of Yersinia pestis Bacteriophage \u03c6A1122 Reveals an Intimate History with the Coliphage T3 and T7 Genomes","volume":"185","author":"Garcia","year":"2003","journal-title":"J. Bacteriol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1099\/mic.0.2007\/006213-0","article-title":"Transcriptome analysis of Yersinia pestis in human plasma: An approach for discovering bacterial genes involved in septicaemic plague","volume":"153","author":"Chauvaux","year":"2007","journal-title":"Microbiology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/1\/89\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:09:38Z","timestamp":1760159378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/1\/89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["v13010089"],"URL":"https:\/\/doi.org\/10.3390\/v13010089","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]}}}